Curis Past Earnings Performance
Past criteria checks 0/6
Curis's earnings have been declining at an average annual rate of -13.8%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 0.3% per year.
Key information
-13.8%
Earnings growth rate
16.2%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 0.3% |
Return on equity | -241.0% |
Net Margin | -473.0% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Curis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 10 | -47 | 19 | 0 |
30 Sep 23 | 10 | -47 | 18 | 0 |
30 Jun 23 | 10 | -48 | 18 | 0 |
31 Mar 23 | 10 | -52 | 19 | 0 |
31 Dec 22 | 10 | -57 | 20 | 0 |
30 Sep 22 | 10 | -59 | 20 | 0 |
30 Jun 22 | 11 | -57 | 20 | 0 |
31 Mar 22 | 11 | -52 | 19 | 0 |
31 Dec 21 | 11 | -45 | 17 | 0 |
30 Sep 21 | 11 | -39 | 16 | 0 |
30 Jun 21 | 10 | -34 | 14 | 0 |
31 Mar 21 | 10 | -30 | 13 | 0 |
31 Dec 20 | 11 | -30 | 12 | 0 |
30 Sep 20 | 11 | -31 | 12 | 0 |
30 Jun 20 | 11 | -31 | 12 | 0 |
31 Mar 20 | 11 | -32 | 12 | 0 |
31 Dec 19 | 10 | -32 | 12 | 0 |
30 Sep 19 | 9 | -29 | 12 | 0 |
30 Jun 19 | 9 | -30 | 13 | 0 |
31 Mar 19 | 10 | -32 | 14 | 0 |
31 Dec 18 | 10 | -33 | 15 | 0 |
30 Sep 18 | 11 | -35 | 15 | 0 |
30 Jun 18 | 11 | -43 | 14 | 0 |
31 Mar 18 | 10 | -48 | 15 | 0 |
31 Dec 17 | 10 | -53 | 14 | 0 |
30 Sep 17 | 9 | -57 | 15 | 0 |
30 Jun 17 | 8 | -70 | 16 | 0 |
31 Mar 17 | 8 | -67 | 16 | 0 |
31 Dec 16 | 8 | -60 | 16 | 0 |
30 Sep 16 | 7 | -63 | 15 | 0 |
30 Jun 16 | 8 | -40 | 13 | 0 |
31 Mar 16 | 8 | -37 | 13 | 0 |
31 Dec 15 | 8 | -59 | 13 | 0 |
30 Sep 15 | 8 | -51 | 13 | 0 |
30 Jun 15 | 7 | -51 | 13 | 0 |
31 Mar 15 | 10 | -45 | 12 | 0 |
31 Dec 14 | 10 | -19 | 12 | 0 |
30 Sep 14 | 9 | -17 | 11 | 0 |
30 Jun 14 | 15 | -14 | 12 | 0 |
31 Mar 14 | 15 | -13 | 12 | 0 |
31 Dec 13 | 15 | -12 | 11 | 0 |
30 Sep 13 | 15 | -20 | 11 | 0 |
30 Jun 13 | 9 | -22 | 11 | 0 |
Quality Earnings: CUS0 is currently unprofitable.
Growing Profit Margin: CUS0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CUS0 is unprofitable, and losses have increased over the past 5 years at a rate of 13.8% per year.
Accelerating Growth: Unable to compare CUS0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CUS0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.7%).
Return on Equity
High ROE: CUS0 has a negative Return on Equity (-241.04%), as it is currently unprofitable.